Dermata Therapeutics Equity Warrant Exp 13th Aug 2023 DRMAW:NASDAQ

RT Quote | NASDAQ | USD
Last | 10/05/22 EDT
0.0661UNCH (UNCH)
Volume
113
52 week range
0.05 - 1.70
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0661
  • 52 Week High1.70
  • 52 Week High Date11/03/21
  • 52 Week Low0.05
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0661
  • 52 Week High1.70
  • 52 Week High Date11/03/21
  • 52 Week Low0.05
  • 52 Week Low Date05/11/22
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Dermata Therapeutics Equity Warrant Exp 13th Aug 2023

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its products candidates, DMT310 and DMT410. Its lead product candidate DMT310, is intended to utilize its Spongilla technology for a once weekly treatment of a variety of skin diseases with its initial focus being for the...
Gerald Proehl
Chairman of the Board, President, Chief Executive Officer
Kyri Van Hoose
Chief Financial Officer, Senior Vice President
Address
3525 Del Mar Heights Rd., #322
San Diego, CA
92130
United States